Nama's AI scorecard currently rates TG Therapeutics Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TGTX's P/E ratio?

TG Therapeutics trades at a trailing price-to-earnings ratio of 112.9.

When does TGTX report earnings?

TG Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.26.

What is the TGTX price target?

The median analyst price target from 7 analysts is $75.00, with a range of $21.00 – $86.00.

Is TGTX Shariah compliant?

Nama's AAOIFI-style screen reads TG Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

TG Therapeutics (TGTX)

Healthcare · Biotechnology · NASDAQ

TG Therapeutics (TGTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $9.16B, a trailing price-to-earnings ratio of 112.9 and a free-cash-flow yield of -0.2%. Over the most recent reported fiscal year, revenue grew 87.3%. Nama's AI scorecard rates it Sell, 4.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 4.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +59.2% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-5.9%

How far the last close sits under the highest price of the past five years.

Market cap	$9.16B
Trailing P/E	112.9
Price / book	15.2
Price / sales	11.5
FCF yield	-0.2%
Dividend yield	—
Gross margin	82.4%
Operating margin	17.1%
Net margin	55.2%
Revenue growth (YoY)	+87.3%
Revenue growth (3-yr annual)	+504.9%
EPS growth (YoY)	+257.1%
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

TGTX earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.26). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 3, 2026	$0.05	$0.44	-88.6%	$240.34M
Q1 2026	May 6, 2026	$0.18	$0.28	-35.7%	$204.92M
Q4 2025	Feb 26, 2026	$0.14	$0.33	-57.6%	$192.57M
Q3 2025	Nov 3, 2025	$0.16	$0.22	-27.3%	$161.71M

TGTX analyst price target

Median target $75.00 from 7 analysts, ranging $21.00 – $86.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live TGTX data on Nama Insights →

TGTX FAQ

Is TGTX a buy?: Nama's AI scorecard currently rates TG Therapeutics Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TGTX's P/E ratio?: TG Therapeutics trades at a trailing price-to-earnings ratio of 112.9.
When does TGTX report earnings?: TG Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.26.
What is the TGTX price target?: The median analyst price target from 7 analysts is $75.00, with a range of $21.00 – $86.00.
Is TGTX Shariah compliant?: Nama's AAOIFI-style screen reads TG Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.